Crystalline DBD Polymorph Combinations for Safer Brain Tumor Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including 1,6-dibromo-1,6-dideoxy-dulcitol (DBD), suffer from safety and efficacy issues due to poor solubility and outdated production methods, necessitating the development of safer and more effective cancer therapies.
Innovation Solution
The use of crystalline polymorphs of DBD in combination with specific anti-cancer moieties, such as Temozolomide, radiation, and targeted therapies, to enhance treatment efficacy and safety profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If DBD is prepared by treating dulcitol with aqueous hydrobromic acid saturated with gaseous hydrogen bromide at temperatures less than 0°C, then DBD can be synthesized, but the production method is no longer considered safe
Solution Approach 1:
The patent changes the synthesis parameters by using alternative reagents and conditions that are safer than the original method. Specifically, it employs bromine water or bromine in acetic acid instead of aqueous hydrobromic acid saturated with gaseous hydrogen bromide, and uses temperatures above 0°C, thereby maintaining manufacturability while eliminating safety hazards.
Solution Approach 2:
The patent introduces intermediary substances (bromine water, acetic acid) as safer alternatives to the original reagents. These intermediaries mediate the bromination reaction to produce DBD without requiring the hazardous aqueous hydrobromic acid and gaseous hydrogen bromide combination, thus resolving the safety issue while preserving the manufacturing capability.
2Reliability
If DBD is used as a chemotherapeutic agent, then it can treat cancer, but it has poor solubility
Solution Approach 1:
The patent creates composite formulations by combining DBD with solubility enhancement agents or formulating it in combination with other chemotherapeutic agents. This composite approach maintains the antitumor efficacy of DBD while improving its solubility and bioavailability through the synergistic effects of the combination formulation.
Solution Approach 2:
The patent changes the physical-chemical parameters of DBD by altering its formulation conditions, pH, or molecular form to improve solubility. It may also modify administration parameters such as dosage frequency or route of administration to optimize both solubility and therapeutic effectiveness.
3Ease of operation
If current drug therapies for metastatic disease are used, then they can provide palliative treatment, but they seldom offer a long-term cure
Solution Approach 1:
The patent merges DBD with other chemotherapeutic agents and targeted therapies to create combination regimens that leverage synergistic effects. This combination approach aims to achieve both palliative relief and long-term cure potential by attacking cancer through multiple mechanisms simultaneously, overcoming the limitations of single-agent therapies.
Solution Approach 2:
The patent develops composite therapeutic regimens that combine DBD with various anti-cancer moieties, creating a multi-component treatment system. This composite formulation provides both immediate palliative benefits and long-term curative potential through the synergistic interactions between different therapeutic agents.
4Reliability
If DBD is used in combination with other anti-cancer moieties, then efficacy can be enhanced, but the complexity of treatment regimens increases
Solution Approach 1:
The patent identifies universal combination partners for DBD that can be applied across different cancer types and treatment settings. By establishing multi-functional combination regimens that work across multiple indications, the patent reduces the need for entirely new regimens for each cancer type, thereby managing complexity while maintaining enhanced efficacy.
Solution Approach 2:
The patent optimizes combination parameters such as dosing ratios, administration timing, and sequence to simplify the treatment regimen while maintaining synergistic efficacy. By carefully tuning these parameters, the patent achieves enhanced cancer treatment effectiveness without proportionally increasing the complexity of administration and monitoring.
Data Source
AI summary
Methods of treating a subject suffering from a brain tumor are described herein wherein said methods comprise administering a therapeutically effective amount of a crystalline polymorph of 1,6-dibromo-1,6-dideoxy-dulcitol (DBD) including combination therapies with synergistic second cancer treatments. Also disclosed are methods of screening subjects sensitive to a crystalline DBD polymorph and treating those subjects demonstrating sensitivity.